Following Kevin Tang’s last HRTX Sell transaction on April 02, 2018, the stock climbed by 11.6%. This is Tang’s first Sell trade following 14 Buy transactions.
Based on Heron Therapeutics’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $17.28 million and GAAP net loss of $38.67 million. In comparison, last year the company earned revenue of $8.51 million and had a GAAP net loss of $42.8 million. Currently, Heron Therapeutics has an average volume of 1.47M.
Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $57.83, reflecting a 58.4% upside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011.